We take exception to the remarks of Gur et al in their recent Progress in Cerebrovascular Disease article (Stroke 13: 750-758, 1982), which may mislead your readership as to the magnitude of the errors associated with xenon CT measurements of rCBF. In discussing our error analysis of the single-scan "autoradiographic" approach to xenon CT rCBF measurements' (an approach originally championed by Gur and his colleagues 2 ), Gur et al fault us for using the fast-flow component, f g , rather than "total flow" as the reference flow in our definition of percent error. They go on to conclude that "if one corrects for this mistake the errors are significantly lower than reported."
those predicted by E, or E 2 . However, as f g and X g decrease (as, for example, in stroke 4 ), the magnitude of E 3 may exceed that of E] or This is especially apt to occur with the longer inhalation/scanning times required to achieve adequate enhancement under low-flow conditions ( fig. 2) must admit that we are proud to have "originally championed the autoradiographic approach to Xenoh/CT LCBF measurements" at a time when most CT scanners were slow 20 seconds scan time) and interscan delays were much longer O 30 sec) than those currently available on many machines. There is no doubt that this method is now outdated. Since 1979-80 we, along with other groups, have been devel oping and using more sophisticated multivariable methods of analysis such as the weighted mono-or bi-compartmental least square fits. We believe that the true flow through a tissue volume should be used as a reference flow in error analyses and therefore, we do agree with Rottenberg, et al that what they define as E2 is the error due to heterogeneity if the mono-compartmental model is used. Rottenberg'S data show that E2 is significantly smaller than E, in tissue with a significant mixture (percent gray ^ 75%). Therefore, the statement we made in our recent review in STROKE is fully supported by their own data. The study of Abdon et al 1 demonstrates that the incidence of finding the heart as the source of a focal cerebral infarction is related to the intensity of investigating the heart as such. In their study on long-term electrocardiographic recording they found a significant higher preva lence of "atriopathic arrhythmias" in a population of stroke patients than in a reference group. Sick sinus syndrome was one of these arrhyth mias and it was present in 19 of 88 stroke patients and in only 9 of 103 patients of the control group. I wonder what strategy the authors apply when sick sinus syndrome is a fortuitous finding, and when it appears to be present in a stroke patient. Is anticoagulant therapy indicated? The authors use the temporal pattern at stroke onset as the only criterium to distinguish embolic from thrombotic infarction and found approximate ly the same percentage of atriopathic arrhythmias in both groups. Does this imply that these arrhythmias occur in patients with thrombotic stroke While the cardiac arrhythmia is not causally related to the occur rence of the stroke, or was the prior clinical diagnosis incorrect and suffered the 15 patients in the supposed thrombotic group in fact a cerebral embolus? This point could be relevant regarding anticoagulant treatment.
Sincerely Yours, Jan Lodder Dept. of Neurology. Rijksuniversiteit Limburg, P.O. Box 616 6200 MD Maastricht the Netherlands
The authors reply:
We are pleased to answer the questions raised by Dr. Lodder. In our report the sick sinus syndrome (SSS) was present in 21 of 86 stroke patients. It has been shown that persons with stroke and SSS, even where the etiological connection is uncertain, have a future risk for cerebral emboli of 7% per individual and year. 1 We therefore find preventive measures advisable where possible and subscribe to the following general policies: 1) If other aggravating drugs are present, i.e. beta blockers or digi talis in the case of sinus bradyarrhythmia, they should be withdrawn and arrhythmia re-evaluated.
2) Where possible, anticoagulants should be given. Due to the high frequency of concomitant disease in this patient group anticoagulants are often inadvisable and individual judgement must be made.
We have followed tradition in classifying stroke which occurs during sleep or with unclear onset as "thrombotic''. Some of these strokes may well have been embolic in origin. Only one patient with a "thrombotic" stroke and atriopathic arrhythmia demonstrated progessive neurological deficit after admission. We are more inclined to regard the classification of stroke as embolic or thrombotic using only anamnestic data as insuffi cient than to consider the presence of atriopathic arrhythmia in the "thrombotic" group as purely coincidental.
Hypertensive Encephalopathy

To the Editor:
Dinsdale, 1 in his recent review of hypertensive encephalopathy (HTE) in this journal; mentions sodium nitroprusside (SNP) as often being the initial drug of choice in the treatment of HTE. While this choice is supported by a large segment of the available neurology and internal medicine literature, we feel that a significant amount of theory and objective information exists that make this drug appear less than optimal. The danger in use of SNP is the same mechanisms as for other direct acting vasodilators: cerebral arteriolar dilation allows delivery of more pressure to the microvascular bed, hence increased edema, and increase in cerebral blood volume (CBV), both of which increase intra cranial pressure (ICP) when intracranial compliance is low. 2 
' 3
There would not be a problem in using SNP in HTE if there was not a problem with either intracranial compliance or ICP. However, this is not the case. In a study reported in 1954, elevated lumbar pressures were found in 39% of patients with HTE. 4 
